Project 2026-D0036

2026-D0036
Clinical Performance Study for Use of the PhenoSense® HIV Monoclonal Antibody (mAb) Assay in Gilead Sciences Phase 3 Clinical Evaluation of Teropavimab and Zinlirvimab in Combination with Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 Infection on Oral Daily Antiretroviral Therapy
multicentric
PD Dr. med. univ. Johannes Nemeth
Universitätsspital Zürich, Zürich
Hôpitaux universitaires de Genève, Service des maladies infectieuses
Unité VIH
Dépa
Centre hospitalier universitaire vaudois, Service des maladies infectieuses
Rue du Bugnon 4
clinical trial
C2
Kantonale Ethikkommission Zürich
Commission cantonale d'Éthique de la Recherche sur l'être humain Vaud (CER-VD), Commission Cantonale d'éthique de la recherche Genève (CCER)
11.08.2026
Gilead Sciences, Inc.
in vitro diagnostic medical devices IVD-MD